Analyst Consensus ?
ConsensusBuy6 ratings
Bullish583.3%
Neutral116.7%
Bearish00.0%
Takeda Pharmaceutical Company Limited · TAK · FY2025 Q4 · Calendar Q2 2026
Takeda Maintains FY26 Outlook as It Prepares Three Launches
Takeda's growth case depends on turning late-stage pipeline progress into launches while cost savings offset continued erosion in mature products. The call supports the opportunity through three planned launches and a transformation program, but launch execution, competition, and pricing remain material uncertainties.
Reported Before market openNYSEHealthcare
$66.68B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$-0.05
Consensus $0.21
EPS surprise
-123.4%
Reported versus consensus
Reported revenue
$6.92B
Consensus $7.14B
Revenue surprise
-3.0%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+1.3%
Event window
SPY move
+0.6%
Same window
Abnormal move
+0.8%
Stock minus SPY
Volume
1.3×
Versus trailing sessions
Subsequent drift
-4.6%
Up to 20 sessions
TAKSPY benchmark
Ask FN2 about TAK FY2025 Q4
Transcript, numbers and history already loaded
Why did TAK rise 1.3% after missing EPS estimates in FY2025 Q4?What changed in TAK's guidance and outlook in FY2025 Q4?Give me the bull and bear case for TAK after FY2025 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management described FY25 as solid despite VYVANSE generic erosion and maintained FY26 guidance. It emphasized planned launches for oveporexton and rusfertide in H2 2026 and zasocitinib beginning in early 2027, alongside a transformation program targeting JPY 100 billion in FY26 savings.
Guidance delta
Maintained FY26 guidance: low-single-digit revenue decline, core operating profit down 5–8%, and stable free cash flow, according to the supplied call analysis.
Key takeaways
- Management cited cost discipline as a support amid VYVANSE generic erosion and pressure on mature brands.
- Oveporexton and rusfertide are planned for U.S. launch in H2 2026; zasocitinib is planned for psoriasis in early 2027 and psoriatic arthritis in FY27.
- The transformation program is expected by management to generate JPY 100 billion in savings in FY26.
- The stated outlook still includes lower revenue and core operating profit, so pipeline progress does not remove near-term operating pressure.
Management priorities
- Prepare the planned launches of oveporexton, rusfertide and zasocitinib.
- Advance late-stage pipeline programs and indication expansions.
- Deliver transformation savings while continuing investment in growth and R&D.
Follow TAK with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| TD Cowen | Outperform | Outperform | Maintain | May 16, 2023 |
| B of A Securities | Buy | Neutral | Upgrade | Mar 16, 2023 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Jul 19, 2022 |
| Morgan Stanley | Equal Weight | Overweight | Downgrade | Oct 7, 2021 |
| JP Morgan | Overweight | Overweight | Maintain | Mar 11, 2020 |
| Jefferies | Buy | Buy | Maintain | Sep 24, 2019 |
Track every rating change on TAK the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationTakeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions.…
Historical context
All TAK earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| NBIX Neurocrine Biosciences, Inc. | FY2026 Q3 · Calendar Q4 2026 | +72.3% | -0.5% | Neurocrine Raises INGREZZA Outlook as Core Products Grow |
| AXSM Axsome Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | +60.6% | -5.8% | Axsome’s Q3 growth broadens, while reimbursement and trial execution remain key tests |
| TEM Tempus AI, Inc. | FY2026 Q3 · Calendar Q4 2026 | +174.7% | +8.7% | Tempus Q3 growth broadens across diagnostics and data |
| IDXX IDEXX Laboratories, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +19.5% | IDEXX raises 2026 outlook as diagnostics, placements and software support growth |
| SNY Sanofi | FY2026 Q3 · Calendar Q4 2026 | +30.8% | +2.8% | Sanofi lifts 2026 outlook as Dupixent and launches drive Q3 growth |
| AZN AstraZeneca PLC | FY2026 Q3 · Calendar Q4 2026 | +7.3% | +7.0% | AstraZeneca pairs solid growth with pipeline investment and restructuring |
Latest beats and misses
Who reports nextBeat on EPS
- MARFY2026 Q3 · November 2, 2026+6.3% EPS+4.3% move
- NBIXFY2026 Q3 · November 2, 2026+72.3% EPS-0.5% move
- AXSMFY2026 Q3 · November 2, 2026+60.6% EPS-5.8% move
- TEMFY2026 Q3 · November 2, 2026+174.7% EPS+8.7% move
- BWXTFY2026 Q3 · November 2, 2026+6.8% EPS-0.2% move
- CUBEFY2026 Q3 · October 29, 2026+2.3% EPS+4.0% move
Missed on EPS
- RYAAYFY2027 Q2 · November 2, 2026-0.3% EPS+2.9% move
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- PINSFY2026 Q3 · October 29, 2026-5.4% EPS-2.8% move
Get the TAK recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-07-30T11:05:30.605655+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-03T02:50:48.022786+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.